A Phase 1b Open-label Three-arm Multi-centre Study To Assess The Safety And Tolerability Of Pf-05212384 (pi3k/Mtor Inhibitor) In Combination With Other Anti-tumour Agents
This study will evaluate PF-05212384 (PI3K/mTOR inhibitor) in combination with either
docetaxel, cisplatin or dacomitinib in select advanced solid tumours. The study will assess
the safety, pharmacokinetics and pharmacodynamics of these combinations in patients with
advanced cancer in order to determine the maximum tolerated dose in each combination.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society